{
    "1696.HK": {
        "short_name": "SISRAM MED",
        "long_name": "Sisram Medical Ltd",
        "summary": "Sisram Medical Ltd, an investment holding company, designs, develops, manufactures, and sells energy-based aesthetic medical and minimally invasive treatment systems in the Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa. It offers a portfolio of treatment systems for non-invasive medical aesthetic treatments, including hair removal, skin rejuvenation, skin resurfacing, vascular and pigmented lesions treatment, tattoo removal, acne treatment, cellulite reduction, body contouring, and skin tightening; and minimally invasive treatments, such as assisted liposuction and fat grafting, and feminine health, as well as treatment of varicose veins and ear, nose, and throat procedures. The company also provides beauty product line treatment systems, such as Rejuve and Reshape; and manufactures, distributes, and sells medical equipment. It offers its products under the Alma, Soprano, Harmony, ClearLift, Accent, BeautiFill, and FemiLift brands. The company sells its products directly to treatment providers and treatment recipients; and through distributors and direct sales. The company was founded in 2013 and is headquartered in Caesarea, Israel. Sisram Medical Ltd operates as a former subsidiary of Ample Up Limited.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "Israel",
        "city": "Caesarea"
    },
    "1BT.F": {
        "short_name": "ENLIVEX THERAP.LTD.IS-,01",
        "long_name": "Enlivex Therapeutics Ltd.",
        "summary": "Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate, which is in Phase IIb clinical trial in patients with severe sepsis; that is in investigator-initiated Phase II clinical trial for the treatment of COVID-19 patients in severe and critical conditions; and which is in Phase IIa clinical trial for the prevention of Graft Versus Host Disease in allogeneic hematopoietic stem cell transplants (HSCT) patients. The company is also developing Allocetra for the prevention of complications associated with bone marrow transplantations and/or HSCT, and acute multiple organ failure. It also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor T-Cell therapy and therapies targeting T-Cell receptor therapy. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Israel",
        "city": "Ness Ziona"
    },
    "2F5.F": {
        "short_name": "BIOND.PHAR.S.ADS/40 IL-01",
        "long_name": "BiondVax Pharmaceuticals Ltd.",
        "summary": "BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which is in Phase III clinical trials for treatment of seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Jerusalem, Israel.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Israel",
        "city": "Jerusalem"
    },
    "2RH.F": {
        "short_name": "REDHILL B.S.ADR 10/IL-,01",
        "long_name": "RedHill Biopharma Ltd.",
        "summary": "RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, with a planned Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), a SK2 selective inhibitor targeting various indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and in Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, a Phase 2-stage serine protease inhibitor for cancer and inflammatory gastrointestinal diseases, and is also being evaluated for COVID-19; and RHB-106, an encapsulated bowel preparation. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Israel",
        "city": "Tel Aviv"
    },
    "2RW.F": {
        "short_name": "REWALK ROBOTICS  IS -,01",
        "long_name": "ReWalk Robotics Ltd.",
        "summary": "ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions. It offers ReWalk Personal for everyday use to paraplegic individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy used in hospitals and rehabilitation centers in the United States and Europe. The company is also developing ReWalk Restore, a soft suit exoskeleton for rehabilitation of individuals suffering from a stroke. It markets and sells its products directly to third party payers, institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was founded in 2001 and is headquartered in Yokneam Ilit, Israel.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Israel",
        "city": "Yokneam Illit"
    },
    "4SG.F": {
        "short_name": "SOL-GEL TECHN. IS-,10",
        "long_name": "Sol-Gel Technologies Ltd.",
        "summary": "Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, which has completed Phase II clinical trials for the treatment of acne vulgaris; Epsolay that has completed Phase II clinical trials for the treatment of papulopustular rosacea; SGT-210, a epidermal growth factor receptor inhibitor, which is in development for the treatment of palmoplantar keratoderma and non-melanoma skin cancer; and tapinarof and roflumilast to treat psoriasis and other dermatological indications. It is also involved in the development of generic topical dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo; and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Israel.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Israel",
        "city": "Ness Ziona"
    },
    "ALMD.TA": {
        "short_name": "ALLIUM MEDICAL SOL",
        "long_name": "Allium Medical Solutions Ltd",
        "summary": "Allium Medical Solutions Ltd., a medical device company, develops, manufactures, and markets minimally invasive products in Israel and internationally. The company offers covered stents, such as ureteral, round posterior, triangular prostatic, bulbar, and biliary stents. It also provides uro-gynecology products, including EndoFast Reliant Systems for reinforcement; EndoFast Resorb kits for fixation of surgical mesh to tissues for tissue reinforcement; EndoFast Reliant MN, an implantable, sub-urethral support sling for the treatment of male stress urinary incontinence; and EndoFast Reliant SCP for fixation of surgical mesh to tissue for tissue reinforcement during laparotomy or laparoscopic Sacrocolpopexy approach. In addition, the company offers gastro-duodenal sleeves for the treatment of diabetes mellitus and obesity; and WIRION EPD system, an embolic protection system. Allium Medical Solutions Ltd. is headquartered in Caesarea, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Caesarea"
    },
    "APOP": {
        "short_name": "Cellect Biotechnology Ltd.",
        "long_name": "Cellect Biotechnology Ltd.",
        "summary": "Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. It is developing the ApoTainer selection kit, a shelf stem cell selection kit for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company has collaborations with the denovoMATRIX group of the Technische Universit\u00c3\u00a4t Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine; and Cell2in Inc. to conduct scientific evaluations combining ApoGraft with Cell2in's identification technology FreSHtracer, which monitors stem cell quality by utilizing a fluorescent dye to characterize their oxidative stress state. It also has a collaboration with the Washington University School of Medicine to determine the safety and tolerability of ApoGraft for bone marrow transplantations in the United States. The company was formerly known as Cellect Biomed Ltd. and changed its name to Cellect Biotechnology Ltd. in July 2016. Cellect Biotechnology Ltd. was founded in 2011 and is headquartered in Kfar Saba, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "Israel",
        "city": "Kfar Saba"
    },
    "AYLA": {
        "short_name": "Ayala Pharmaceuticals, Inc.",
        "long_name": "Ayala Pharmaceuticals, Inc.",
        "summary": "Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was founded in 2017 and is based in Rehovot, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Israel",
        "city": "Rehovot"
    },
    "BAV.F": {
        "short_name": "BATM ADV. COMMCTNS IS-,01",
        "long_name": "BATM Advanced Communications Ltd.",
        "summary": "BATM Advanced Communications Ltd., together with its subsidiaries, provides real-time technologies for networking solutions and bio-medical systems in Israel, the United States, and Europe. It operates in two divisions, Networking and Cyber, and Bio-Medical. The Networking and Cyber division is involved in the research and development, production, and marketing of data communication products, including network function virtualization in the fields of local and wide area networks, and premises management systems. This division provides ICT solutions and services; and cyber security solutions. It also offers software services, such as training, technical support and maintenance related to the communication products, mobile and Web solutions, UI, UX design, branding, graphical design, and drivers and embedded solutions; and construction contracts. The Bio-Medical division engages in the research and development, production, marketing, and distribution of medical products, such as laboratory diagnostics and sterilization equipment. This division offers molecular biology diagnostics; provides solutions to treat pathogenic and medical waste in laboratories and hospitals, as well as for pharmaceutical manufacturing plants and agricultural applications; and distributes diagnostic equipment and medical supplies of various brands. BATM Advanced Communications Ltd. has a collaboration with Novamed Ltd for the joint development and marketing of a home-use testing kit for COVID-19. The company was founded in 1992 and is headquartered in Hod Hasharon, Israel.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Israel",
        "city": "Hod HaSharon"
    },
    "BBIXF": {
        "short_name": "BONUS BIOGROUP LTD",
        "long_name": "Bonus BioGroup Ltd.",
        "summary": "Bonus BioGroup Ltd., a biotechnology company, develops technology solutions to generate tissue-regenerating bone grafts. It develops tissue-regenerating bone grafts from cells derived from the patient's own cells for the treatment of skeletal disorders, such as bone and cartilage related arthritis, as well as various types of bone and joint trauma. The company's products include BonoFill injectable bone graft that is suitable for bone repair applications, including jaw bone cysts; and BonoFill pre-designed bone graft, which is used to repair large/segmental bone defects. Its products in pipeline comprise bone grafts for maxillofacial and orthopedic applications; novel nanomaterials technology for tissue regeneration; and large vascularized bone grafts. The company was formerly known as Oceana Advanced Industries Ltd. and changed its name to Bonus BioGroup Ltd. Bonus BioGroup Ltd. was founded in 1981 and is based in Haifa, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Haifa"
    },
    "BIOV.TA": {
        "short_name": "BIO VIEW",
        "long_name": "Bio-View Ltd",
        "summary": "Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company's products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatically scans, analyses, and sorts a range of FISH samples in real-time; and Allegro Plus, an automatic fluorescent imaging system, which identifies various chromosomal aberrations under fluorescent light, such as amplifications, translocations, inversions, and deletions. It also offers DUET-3, an imaging and analysis platform that boasts an automated barcode reader, which enables scanning of various test types in a single scan batch; DeNovo, an automated scanning system for detection, analysis, and characterization of circulating tumor cells from peripheral blood; and Solo Workstation, an offline workstation that streamlines and enables review and analysis of test results away from the microscope. In addition, the company provides Solo Touch Workstation, an offline workstation, which streamlines the review and analysis of test results away from the microscope and on an intuitive touch screen; and SoloWeb, an online remote workstation that analyses, reports, and consults on BioView-scanned cases using web browsers various locations. Bio-View Ltd was founded in 2000 and is based in Rehovot, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Rehovot"
    },
    "BLRX": {
        "short_name": "BioLineRx Ltd.",
        "long_name": "BioLineRx Ltd.",
        "summary": "BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech's TECENTRIQ (Atezolizumab) in Phase 1b/2 studies for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Modi'in, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Hevel Modi'in"
    },
    "BLRX.TA": {
        "short_name": "BIOLINE RX LTD",
        "long_name": "BioLineRx Ltd.",
        "summary": "BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech's TECENTRIQ (Atezolizumab) in Phase 1b/2 studies for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Modi'in, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Hevel Modi'in"
    },
    "BOLT.TA": {
        "short_name": "BIOLIGHT LIFE SCI",
        "long_name": "BioLight Life Sciences Ltd.",
        "summary": "BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions comprising glaucoma, dry eye syndrome, and age-related macular degeneration. The company's ophthalmic product offering and pipeline of product candidates include IOPtiMate, a laser-based surgical treatment for glaucoma; TeaRx, a point-of-care multi-parameter diagnostic test for DES; Eye-D, a controlled release drug-delivery insert platform; OphRx, a non-invasive topical drug delivery technology; and LipiTear, a micro-emulsion vehicle for the dry eye treatment, as well as for the treatment of other ocular diseases. It also invests in cancer diagnostics technologies, including proprietary tests that are designated for bladder, cervical, multiple myeloma, and other cancers. The company was formerly known as Bio Light Israeli Life Sciences Investments Ltd. and changed its name to BioLight Life Sciences Ltd. in February 2016. BioLight Life Sciences Ltd. was founded in 2005 and is based in Tel Aviv, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Tel Aviv"
    },
    "BRSYF": {
        "short_name": "BRAINSWAY LTD",
        "long_name": "Brainsway Ltd.",
        "summary": "Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Jerusalem"
    },
    "BTAVF": {
        "short_name": "BATM ADVANCED COMMUNICATIONS",
        "long_name": "BATM Advanced Communications Ltd.",
        "summary": "BATM Advanced Communications Ltd., together with its subsidiaries, provides real-time technologies for networking solutions and bio-medical systems in Israel, the United States, and Europe. It operates in two divisions, Networking and Cyber, and Bio-Medical. The Networking and Cyber division is involved in the research and development, production, and marketing of data communication products, including network function virtualization in the fields of local and wide area networks, and premises management systems. This division provides ICT solutions and services; and cyber security solutions. It also offers software services, such as training, technical support and maintenance related to the communication products, mobile and Web solutions, UI, UX design, branding, graphical design, and drivers and embedded solutions; and construction contracts. The Bio-Medical division engages in the research and development, production, marketing, and distribution of medical products, such as laboratory diagnostics and sterilization equipment. This division offers molecular biology diagnostics; provides solutions to treat pathogenic and medical waste in laboratories and hospitals, as well as for pharmaceutical manufacturing plants and agricultural applications; and distributes diagnostic equipment and medical supplies of various brands. BATM Advanced Communications Ltd. has a collaboration with Novamed Ltd for the joint development and marketing of a home-use testing kit for COVID-19. The company was founded in 1992 and is headquartered in Hod Hasharon, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Hod HaSharon"
    },
    "BVC.L": {
        "short_name": "BATM ADVANCED COMMUNICATIONS LD",
        "long_name": "BATM Advanced Communications Ltd.",
        "summary": "BATM Advanced Communications Ltd., together with its subsidiaries, provides real-time technologies for networking solutions and bio-medical systems in Israel, the United States, and Europe. It operates in two divisions, Networking and Cyber, and Bio-Medical. The Networking and Cyber division is involved in the research and development, production, and marketing of data communication products, including network function virtualization in the fields of local and wide area networks, and premises management systems. This division provides ICT solutions and services; and cyber security solutions. It also offers software services, such as training, technical support and maintenance related to the communication products, mobile and Web solutions, UI, UX design, branding, graphical design, and drivers and embedded solutions; and construction contracts. The Bio-Medical division engages in the research and development, production, marketing, and distribution of medical products, such as laboratory diagnostics and sterilization equipment. This division offers molecular biology diagnostics; provides solutions to treat pathogenic and medical waste in laboratories and hospitals, as well as for pharmaceutical manufacturing plants and agricultural applications; and distributes diagnostic equipment and medical supplies of various brands. BATM Advanced Communications Ltd. has a collaboration with Novamed Ltd for the joint development and marketing of a home-use testing kit for COVID-19. The company was founded in 1992 and is headquartered in Hod Hasharon, Israel.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "Israel",
        "city": "Hod HaSharon"
    },
    "BVXV": {
        "short_name": "BiondVax Pharmaceuticals Ltd.",
        "long_name": "BiondVax Pharmaceuticals Ltd.",
        "summary": "BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which is in Phase III clinical trials for treatment of seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Jerusalem, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "Israel",
        "city": "Jerusalem"
    },
    "BWAY": {
        "short_name": "Brainsway Ltd.",
        "long_name": "Brainsway Ltd.",
        "summary": "Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Israel",
        "city": "Jerusalem"
    },
    "BWAY.TA": {
        "short_name": "BRAINSWAY LTD",
        "long_name": "Brainsway Ltd.",
        "summary": "Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Jerusalem"
    },
    "CANF": {
        "short_name": "Can-Fite Biopharma Ltd Sponsore",
        "long_name": "Can-Fite BioPharma Ltd.",
        "summary": "Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "Israel",
        "city": "Petah Tikva"
    },
    "CANF.TA": {
        "short_name": "CAN FITE BIOPHARMA",
        "long_name": "Can-Fite BioPharma Ltd.",
        "summary": "Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Petah Tikva"
    },
    "CBI.TA": {
        "short_name": "CLAL BIOTECHNOLOGY",
        "long_name": "Clal Biotechnology Industries Ltd.",
        "summary": "Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical; incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It prefers to invest in life sciences, medical devices, biopharmaceutical technologies, and biotechnology companies. The firm seeks to invest in companies based in United States, and Israel. It invests between $0.5 million and $10 million per company. It takes a seat on the board of directors of the companies it invests in. It invests through personal capital of its management. The firm acts as a lead investor and major shareholder in its portfolio companies. Clal Biotechnology Industries Ltd. was founded in July, 1998 and is based in Tel Aviv, Israel with an additional office in Cambridge, Massachusetts. It operates as a former subsidiary of Clal Industries and Investments Ltd.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Tel Aviv"
    },
    "CGEN": {
        "short_name": "Compugen Ltd.",
        "long_name": "Compugen Ltd.",
        "summary": "Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Holon"
    },
    "CGEN.TA": {
        "short_name": "COMPUGEN",
        "long_name": "Compugen Ltd.",
        "summary": "Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Holon"
    },
    "CHEK": {
        "short_name": "Check-Cap Ltd.",
        "long_name": "Check-Cap Ltd.",
        "summary": "Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface. The company was founded in 2004 and is based in Isfiya, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Isfiya"
    },
    "CKNTF": {
        "short_name": "CELL KINETICS LTD",
        "long_name": "Cell Kinetics Ltd.",
        "summary": "Cell Kinetics Ltd. engages in the refining and commercialization of CellScan and related technology. It focuses on the development and commercialization of a cell carrier technology known as CKChip, a platform static cytometry technology that enables the simultaneous examination of various individual live cells using simple imaging methods, such as fluorescence microscopy. The company was founded in 1992 and is headquartered in Lod, Israel. Cell Kinetics Ltd. is a subsidiary of Medis Technologies Ltd.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Lod"
    },
    "CLGN": {
        "short_name": "CollPlant Biotechnologies Ltd.",
        "long_name": "CollPlant Biotechnologies Ltd.",
        "summary": "CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bio-printing of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. The company's products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. Its products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants; VergenixSTR, a soft tissue repair matrix intended for treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Rehovot"
    },
    "CNMD.TA": {
        "short_name": "CANNOMED MEDICAL",
        "long_name": "Cannomed Medical Cannabis Industries LTD",
        "summary": "Cannomed Medical Cannabis Industries Ltd, a biopharmaceutical company, discovers and develops novel therapeutics. It focuses on discovering inhibitors for E3 ubiquitin ligases for the treatment of cancer, metabolic diseases, viral infection, and CNS related disorders. The company was founded in 1999 and is based in Rehovot, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Rehovot"
    },
    "CNZN.TA": {
        "short_name": "CANZON ISRAEL LTD",
        "long_name": "Canzon Israel Ltd",
        "summary": "Canzon Israel Ltd manages and operates Internet sites in Israel. It offers various tools, such as forums, blogs, and video sharing platforms to users. The company also provides design and development services for Internet and mobile sectors. It serves corporations and large companies, technology product companies, and start-up customers. The company distributes its products through sales people, events, and cooperation agreements. The company was formerly known as User Trend Ltd. Canzon Israel Ltd was founded in 1999 and is based in Bnei Brak, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Jaffa"
    },
    "CPTA.F": {
        "short_name": "COLL.BIO. SP.ADR/1 -,01",
        "long_name": "CollPlant Biotechnologies Ltd.",
        "summary": "CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bio-printing of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. The company's products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. Its products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants; VergenixSTR, a soft tissue repair matrix intended for treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Israel",
        "city": "Rehovot"
    },
    "DANE.TA": {
        "short_name": "DANEL-ADIR YEHOSHU",
        "long_name": "Danel (Adir Yeoshua) Ltd",
        "summary": "Danel (Adir Yeoshua) Ltd provides human resources services in Israel. It offers recruitment, placement, and employment services in the areas of employment, nursing, welfare, education, hi-tech, cleantech, biotech, finance, and others; and nursing services, such as nursing law services, private care in hospitals, private care by caregivers, assistance to holocaust survivors and foreign caregivers. The company also operates a social-rehabilitation day club, which provides social and recreational activities for the victims of hostile acts, as well as offers housing, education, employment, and other services. It serves government ministries, public bodies, the defense industries, and private companies. Danel (Adir Yeoshua) Ltd was founded in 1974 and is based in Ramat Gan, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Ramat Gan"
    },
    "DRIO": {
        "short_name": "DarioHealth Corp.",
        "long_name": "DarioHealth Corp.",
        "summary": "DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The company's flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Blood Glucose Monitoring System, a pocket-sized, blood glucose monitoring device. It offers DarioEngage software platform, where the company digitally engages with Dario users and assists them in monitoring their chronic illnesses, as well as provides them with coaching, support, digital communications; and real time alerts, trends, and pattern analysis. DarioHealth Corp. markets its products directly to consumer cash sales, as well as retail pharmacy, hospitals, and distributors; and through online. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is headquartered in Caesarea, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Caesarea"
    },
    "EFNC.TA": {
        "short_name": "ERECH FINANCE",
        "long_name": "Erech Finance Cahalacha Ltd",
        "summary": "Erech Finance Cahalacha Ltd operates as a medical equipment company. It provides therapeutic medical devices for diabetes. The company is based in Jerusalem, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Jerusalem"
    },
    "EMITF": {
        "short_name": "ELBIT IMAGING LTD",
        "long_name": "Elbit Imaging Ltd.",
        "summary": "Elbit Imaging Ltd., together with its subsidiaries, engages in research and development, production, and marketing of treatment-oriented medical systems; and products to treat cancer diseases. Its treatment-oriented medical systems include magnetic resonance imaging for the purpose of performing noninvasive treatments in human beings. The company is also involved in the sale of plots in India. It has operations in the United States, Europe, and internationally. The company was founded in 1996 and is headquartered in Petach Tikva, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Petach Tikva"
    },
    "EMITF.TA": {
        "short_name": "ELBIT IMAGING LTD",
        "long_name": "Elbit Imaging Ltd.",
        "summary": "Elbit Imaging Ltd., together with its subsidiaries, engages in research and development, production, and marketing of treatment-oriented medical systems; and products to treat cancer diseases. Its treatment-oriented medical systems include magnetic resonance imaging for the purpose of performing noninvasive treatments in human beings. The company is also involved in the sale of plots in India. It has operations in the United States, Europe, and internationally. The company was founded in 1996 and is headquartered in Petach Tikva, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Petach Tikva"
    },
    "EMTC.TA": {
        "short_name": "ELBIT MEDICAL TECH",
        "long_name": "Elbit Medical Technologies Ltd",
        "summary": "Elbit Medical Technologies Ltd engages in the biomedical business. The company is developing an MR-guided ultrasound treatment platform to address various neurosurgery, oncology, and gynecology indications in noninvasive and personalized treatments. It is also involved in the development of therapeutic products based on cells derived from the umbilical cord blood. The company is based in Petah Tikva, Israel. Elbit Medical Technologies Ltd is a subsidiary of Elbit Imaging Ltd.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Petah Tikva"
    },
    "ENLV": {
        "short_name": "Enlivex Therapeutics Ltd.",
        "long_name": "Enlivex Therapeutics Ltd.",
        "summary": "Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate, which is in Phase IIb clinical trial in patients with severe sepsis; that is in investigator-initiated Phase II clinical trial for the treatment of COVID-19 patients in severe and critical conditions; and which is in Phase IIa clinical trial for the prevention of Graft Versus Host Disease in allogeneic hematopoietic stem cell transplants (HSCT) patients. The company is also developing Allocetra for the prevention of complications associated with bone marrow transplantations and/or HSCT, and acute multiple organ failure. It also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor T-Cell therapy and therapies targeting T-Cell receptor therapy. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Ness Ziona"
    },
    "ENLV.TA": {
        "short_name": "ENLIVEX THERAPEUTI",
        "long_name": "Enlivex Therapeutics Ltd.",
        "summary": "Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate, which is in Phase IIb clinical trial in patients with severe sepsis; that is in investigator-initiated Phase II clinical trial for the treatment of COVID-19 patients in severe and critical conditions; and which is in Phase IIa clinical trial for the prevention of Graft Versus Host Disease in allogeneic hematopoietic stem cell transplants (HSCT) patients. The company is also developing Allocetra for the prevention of complications associated with bone marrow transplantations and/or HSCT, and acute multiple organ failure. It also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor T-Cell therapy and therapies targeting T-Cell receptor therapy. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Ness Ziona"
    },
    "ENTX": {
        "short_name": "Entera Bio Ltd.",
        "long_name": "Entera Bio Ltd.",
        "summary": "Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase II clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. The company was founded in 2009 and is based in Jerusalem, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Jerusalem"
    },
    "EVGN": {
        "short_name": "Evogene Ltd.",
        "long_name": "Evogene Ltd.",
        "summary": "Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Application segment develops enhanced castor bean seeds to serve as a feedstock source for biofuel and other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and multi drug resistant organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Rehovot"
    },
    "EVGN.TA": {
        "short_name": "EVOGENE LTD",
        "long_name": "Evogene Ltd.",
        "summary": "Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Application segment develops enhanced castor bean seeds to serve as a feedstock source for biofuel and other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and multi drug resistant organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Rehovot"
    },
    "GLMD": {
        "short_name": "Galmed Pharmaceuticals Ltd.",
        "long_name": "Galmed Pharmaceuticals Ltd.",
        "summary": "Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in ARREST Phase III pivotal study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity, and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; and a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol. The company was founded in 2000 and is headquartered in Tel Aviv-Yafo, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Tel Aviv"
    },
    "GMDA": {
        "short_name": "Gamida Cell Ltd.",
        "long_name": "Gamida Cell Ltd.",
        "summary": "Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a nicotinamide expanded hematopoietic stem cells and differentiated immune cells, including T cells that is in Phase 3 studies in patients with high-risk hematologic malignancies, as well as in Phase 1/2 clinical trial in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Israel",
        "city": "Jerusalem"
    },
    "GOHO.TA": {
        "short_name": "GOLDEN HOUSE",
        "long_name": "Golden House Ltd",
        "summary": "Golden House Ltd provides assisted independent living services for elderly population in Israel. It operates The Golden Age House TA, an assisted independent living house that contains 300 housing units, as well as public spaces, including a lobby, club, restaurant, coffee shop, library, movie theatre, synagogue, classroom, lecture room, fitness center, spa, and green garden terrace. The company also offers nursing care services. Golden House Ltd was founded in 1982 and is based in Tel-Aviv, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Tel-Aviv"
    },
    "HDST.TA": {
        "short_name": "HBL-HADASIT BIO",
        "long_name": "Hadasit Bio-Holdings Ltd",
        "summary": "Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. The company primarily focuses on the therapeutic areas, such as oncology, regenerative medicine, and inflammatory disease. The company was founded in 2005 and is based in Jerusalem, Israel. Hadasit Bio-Holdings Ltd is a subsidiary of Hadasit Ltd.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Jerusalem"
    },
    "HSITF": {
        "short_name": "HBL - HADASIT BIO HOLDINGS LTD",
        "long_name": "Hadasit Bio-Holdings Ltd",
        "summary": "Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. The company primarily focuses on the therapeutic areas, such as oncology, regenerative medicine, and inflammatory disease. The company was founded in 2005 and is based in Jerusalem, Israel. Hadasit Bio-Holdings Ltd is a subsidiary of Hadasit Ltd.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Jerusalem"
    },
    "HUMX.TA": {
        "short_name": "HUMAN XTENSIONS LT",
        "long_name": "Human Xtensions Ltd.",
        "summary": "Human Xtensions Ltd. develops unmediated surgical systems. It offers HandX, a handheld medical device for use in laparoscopic procedures. The company was founded in 2012 and is based in Netanya, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Netanya"
    },
    "ICCM.TA": {
        "short_name": "ICECURE MEDICAL LT",
        "long_name": "IceCure Medical Ltd",
        "summary": "IceCure Medical Ltd develops and markets minimally invasive cryoablation therapies for women's health and oncology markets. The company offers ProSense system, a cryoablation solution for breast tumors. The company was founded in 2006 and is headquartered in Caesarea, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Caesarea"
    },
    "ICUSF": {
        "short_name": "ICECURE MEDICAL LTD",
        "long_name": "IceCure Medical Ltd",
        "summary": "IceCure Medical Ltd develops and markets minimally invasive cryoablation therapies for women's health and oncology markets. The company offers ProSense system, a cryoablation solution for breast tumors. IceCure Medical Ltd was founded in 2006 and is headquartered in Caesarea, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Caesarea"
    },
    "IDTA": {
        "short_name": "IDENTA CORP",
        "long_name": "IDenta Corp.",
        "summary": "IDenta Corp. manufactures and sells detection and forensic science equipment worldwide. The company offers drug, explosives, and bullet-hole testing kits; precursors of drugs test kits; and portable sniffers. It provides its solutions to law enforcement, military, and government agencies, as well as other organizations that deal in fighting illicit drugs and terrorist threats. IDenta Corp. is based in Jerusalem, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Jerusalem"
    },
    "IGAP": {
        "short_name": "INTEGRITY APPLICATIONS INCORPOR",
        "long_name": "Integrity Applications, Inc.",
        "summary": "Integrity Applications, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Europe and the Asia Pacific. It develops GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics in obtaining blood glucose level readings without the pain. The company was founded in 2001 and is based in Ashdod, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Ashdod"
    },
    "IMCC.CN": {
        "short_name": "IMCannabisCorp",
        "long_name": "IM Cannabis Corp.",
        "summary": "IM Cannabis Corp. focuses on breeding, growing, and supply of medical cannabis products in Israel and Germany. Its products include strains and oils. The company also offers its intellectual property related services to the medical cannabis industry. IM Cannabis Corp. is based in Tel Aviv, Israel.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "Israel",
        "city": "Tel Aviv"
    },
    "IMCNF": {
        "short_name": "IM CANNABIS CORP",
        "long_name": "IM Cannabis Corp.",
        "summary": "IM Cannabis Corp. focuses on breeding, growing, and supply of medical cannabis products in Israel and Germany. Its products include strains and oils. The company also offers its intellectual property related services to the medical cannabis industry. IM Cannabis Corp. is based in Tel Aviv, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Tel Aviv"
    },
    "IMED-L.TA": {
        "short_name": "IIM INFINITY L",
        "long_name": "I.I.M. Infinity Innonation Medical - Limited Partnership",
        "summary": "I.I.M. Infinity Innonation Medical - Limited Partnership, a research and development partnership, focuses on investing in research projects and development in the medical field, primarily the health field. The company was incorporated in 2020 and is based in Tel Aviv, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Tel Aviv"
    },
    "INCR.TA": {
        "short_name": "INTERCURE LTD",
        "long_name": "InterCure Ltd",
        "summary": "InterCure Ltd engages in the research, cultivation, production, marketing, and distribution of cannabis products for medical use in Israel and internationally. It also invests in bioscience, life sciences, medical equipment, and biotechnology sectors. The company was incorporated in 1994 and is based in Herzliya, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Herzliya"
    },
    "INMD": {
        "short_name": "InMode Ltd.",
        "long_name": "InMode Ltd.",
        "summary": "InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. InMode Ltd. offers its products directly in the United States, Canada, the United Kingdom, Spain, Australia, and India, as well as indirectly through distributors in 46 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Yokneam"
    },
    "IRCLF": {
        "short_name": "INTERCURE LTD",
        "long_name": "InterCure Ltd.",
        "summary": "InterCure Ltd. invests in the biomedical, life sciences, and biotechnology sectors in Israel and internationally. The company was formerly known as Ben Gavish Ltd. and changed its name to InterCure Ltd. in June 1997. InterCure Ltd. was founded in 1994 and is based in Hadera, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Herzliya"
    },
    "IRME": {
        "short_name": "IR-MED INC",
        "long_name": "IR-Med Inc.",
        "summary": "IR-Med Inc., a medical device company, focuses on the development of infra-red (IR) and artificial intelligence technologies to address the diagnosis of common medical ailments. It offers PressureSafe, a non-invasive and real-time optical monitoring device for the preemptive detection of pressure injury; and Nobiotics, an advanced otoscope that works on IR-spectrographic analysis technology providing doctors an immediate indication of the infection being viral or bacterial. The company also engages in developing a real-time noninvasive optical monitor to determine Propofol blood concentration. IR-Med Inc. is based in Rosh Pinna, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Rosh Pinna"
    },
    "ITMMF": {
        "short_name": "ITAMAR MEDICAL LTD",
        "long_name": "Itamar Medical Ltd.",
        "summary": "Itamar Medical Ltd. engages in the research, development, marketing, sale, and leasing of non-invasive medical devices for the cardiology market. The company offers medical devices based on Peripheral Arterial Tone (PAT) signal, which measures changes in the patient's peripheral arterial pulse volumes and various parameters of arterial activities. It provides WatchPAT device, which enables home sleep tests for various sleeping disorders, including obstructive sleep apnea; and Endo PAT device that diagnoses endothelial dysfunction. The company operates in the United States, Canada, Europe, Israel, Japan, the Asia Pacific, and other countries. Itamar Medical Ltd. has a collaboration agreement with SoClean Inc. to offer WatchPAT ONE home sleep apnea test and digital health services through direct-to-consumer channels. The company was formerly known as Itamar Medical (CM) 1997 Ltd. and changed its name to Itamar Medical Ltd. in July 2000. Itamar Medical Ltd. was founded in 1997 and is headquartered in Caesarea, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Caesarea"
    },
    "ITMR": {
        "short_name": "Itamar Medical Ltd. - American ",
        "long_name": "Itamar Medical Ltd.",
        "summary": "Itamar Medical Ltd. engages in the research, development, marketing, sale, and leasing of non-invasive medical devices for the cardiology market. The company offers medical devices based on Peripheral Arterial Tone (PAT) signal, which measures changes in the patient's peripheral arterial pulse volumes and various parameters of arterial activities. It provides WatchPAT device, which enables home sleep tests for various sleeping disorders, including obstructive sleep apnea; and Endo PAT device that diagnoses endothelial dysfunction. The company operates in the United States, Canada, Europe, Israel, Japan, the Asia Pacific, and other countries. Itamar Medical Ltd. has a collaboration agreement with SoClean Inc. to offer WatchPAT ONE home sleep apnea test and digital health services through direct-to-consumer channels. The company was formerly known as Itamar Medical (CM) 1997 Ltd. and changed its name to Itamar Medical Ltd. in July 2000. Itamar Medical Ltd. was founded in 1997 and is headquartered in Caesarea, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Caesarea"
    },
    "ITMR.TA": {
        "short_name": "ITAMAR MEDICAL LTD",
        "long_name": "Itamar Medical Ltd.",
        "summary": "Itamar Medical Ltd. engages in the research, development, marketing, sale, and leasing of non-invasive medical devices for the cardiology market. The company offers medical devices based on Peripheral Arterial Tone (PAT) signal, which measures changes in the patient's peripheral arterial pulse volumes and various parameters of arterial activities. It provides WatchPAT device, which enables home sleep tests for various sleeping disorders, including obstructive sleep apnea; and Endo PAT device that diagnoses endothelial dysfunction. The company operates in the United States, Canada, Europe, Israel, Japan, the Asia Pacific, and other countries. Itamar Medical Ltd. has a collaboration agreement with SoClean Inc. to offer WatchPAT ONE home sleep apnea test and digital health services through direct-to-consumer channels. The company was formerly known as Itamar Medical (CM) 1997 Ltd. and changed its name to Itamar Medical Ltd. in July 2000. Itamar Medical Ltd. was founded in 1997 and is headquartered in Caesarea, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Caesarea"
    },
    "KDST.TA": {
        "short_name": "KADIMASTEM",
        "long_name": "Kadimastem Ltd",
        "summary": "Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and encapsulated islet-of-langerhans-like clusters for diabetes. The company was founded in 2009 and is based in Ness Ziona, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Ness Ziona"
    },
    "KMDA": {
        "short_name": "Kamada Ltd.",
        "long_name": "Kamada Ltd.",
        "summary": "Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus, as well as human transferrin that is used as a cultural medium for diagnostic assays and cell cultures. In addition, the company distributes Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; IVIG 5% for the treatment of various immunodeficiency-related conditions; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for the prevention of hepatitis B virus; Megalotect, a CMV immunoglobulin; and RUCONEST for the treatment of acute angioedema attacks in adults with hereditary angioedema. Further, it distributes Heparin sodium injection to treat thrombo-embolic disorders; Albumin and Albumin 4% for maintenance of blood plasma; and coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. The company's products in pipeline are G1-AAT (IV) for graft versus host disease and L1-AAT (1V) for lung transparent that are in Phase II stage; and Inhaled AAT for AAT deficiency, which is in Phase II and III stages. It markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceutical Company Limited; PARI GmbH; and Kedrion Biopharma. The company was founded in 1990 and is headquartered in Rehovot, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Rehovot"
    },
    "KMDA.TA": {
        "short_name": "KAMADA LTD",
        "long_name": "Kamada Ltd.",
        "summary": "Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus, as well as human transferrin that is used as a cultural medium for diagnostic assays and cell cultures. In addition, the company distributes Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; IVIG 5% for the treatment of various immunodeficiency-related conditions; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for the prevention of hepatitis B virus; Megalotect, a CMV immunoglobulin; and RUCONEST for the treatment of acute angioedema attacks in adults with hereditary angioedema. Further, it distributes Heparin sodium injection to treat thrombo-embolic disorders; Albumin and Albumin 4% for maintenance of blood plasma; and coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. The company's products in pipeline are G1-AAT (IV) for graft versus host disease and L1-AAT (1V) for lung transparent that are in Phase II stage; and Inhaled AAT for AAT deficiency, which is in Phase II and III stages. It markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceutical Company Limited; PARI GmbH; and Kedrion Biopharma. The company was founded in 1990 and is headquartered in Rehovot, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Rehovot"
    },
    "M8W.F": {
        "short_name": "MEDIWOUND LTD  IS-,01",
        "long_name": "MediWound Ltd.",
        "summary": "MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Israel",
        "city": "Yavne"
    },
    "MDGS": {
        "short_name": "Medigus Ltd.",
        "long_name": "Medigus Ltd.",
        "summary": "Medigus Ltd., a medical device company, develops, produces, and markets minimally invasive endo-surgical tools and direct visualization technology in the United States, Europe, Asia, and internationally. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. Medigus Ltd. was founded in 1999 and is headquartered in Omer, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NCM",
        "market": "us_market",
        "country": "Israel",
        "city": "Omer"
    },
    "MDGS.TA": {
        "short_name": "MEDIGUS",
        "long_name": "Medigus Ltd.",
        "summary": "Medigus Ltd., a medical device company, develops, produces, and markets minimally invasive endo-surgical tools and direct visualization technology in the United States, Europe, Asia, and internationally. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. Medigus Ltd. was founded in 1999 and is headquartered in Omer, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Omer"
    },
    "MDWD": {
        "short_name": "MediWound Ltd.",
        "long_name": "MediWound Ltd.",
        "summary": "MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Yavne"
    },
    "MRHL.TA": {
        "short_name": "MERCHAVIA HOLD",
        "long_name": "Merchavia Holdings and Investments Ltd.",
        "summary": "Merchavia Holdings and Investments Ltd. invests in life science companies in Israel. Merchavia Holdings and Investments Ltd. has a strategic partnership with Cleveland clinic in the United States. The company was formerly known as Nepco Star Ltd. and changed its name to Merchavia Holdings and Investments Ltd. in November 2014. Merchavia Holdings and Investments Ltd. was founded in 1972 and is based in Bnei Brak, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Bnei Brak"
    },
    "NISA.TA": {
        "short_name": "NISSAN",
        "long_name": "Nissan Medical Industries Ltd.",
        "summary": "Nissan Medical Industries Ltd., through its subsidiary, produces and sells spun lace non-woven fabrics in the United States, Canada, Europe, and Israel. Its products are used in wipes, medical products, automotive, and hygienic industries. The company sells its products through its sales agents. Nissan Medical Industries Ltd. was founded in 1984 and is based in Tel Aviv, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Tel Aviv"
    },
    "NNOX": {
        "short_name": "NANO-X IMAGING LTD",
        "long_name": "Nano-X Imaging Ltd.",
        "summary": "Nano-X Imaging Ltd. engages in developing and producing X-ray source technology for the medical imaging industry in the United States. It develops novel digital X-ray source, a microelectromechanical system-based semiconductor cathode that achieves electron emission by a non-thermionic low-voltage trigger to nano-scale molybdenum cones. The company also develops a prototype of the Nanox.ARC, a medical imaging system incorporating its novel digital X-ray source; and Nanox.CLOUD, a companion cloud software designed to deliver medical screening as a service. Nano-X Imaging Ltd. was incorporated in 2018 and is based in Neve Ilan, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Neve Ilan"
    },
    "NSPR": {
        "short_name": "InspireMD Inc.",
        "long_name": "InspireMD, Inc.",
        "summary": "InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. is headquartered in Tel Aviv, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "ASE",
        "market": "us_market",
        "country": "Israel",
        "city": "Tel Aviv"
    },
    "NTEC": {
        "short_name": "Intec Pharma Ltd.",
        "long_name": "Intec Pharma Ltd",
        "summary": "Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program; and a feasibility agreement with GW Research Limited to explore an undisclosed research program using the Accordion Pill platform. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was founded in 2000 and is based in Jerusalem, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "Israel",
        "city": "Jerusalem"
    },
    "NVLG.TA": {
        "short_name": "NOVOLOG",
        "long_name": "Novolog (Pharm-Up 1966) Ltd",
        "summary": "Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. It offers medical devices to healthcare institutions and patients in their homes; and medical logistics services to pharmaceutical and medical device companies. The company also produces and disseminates medical content and tools to the general public and medical community; and develops personalized treatment programs and initiates home visits by nurses. In addition, it provides health and medical process management services for corporations; and supplies sterilization services using ethylene oxide gas for medical and laboratory products, as well as offers direct access to health and wellness ecosystem for international corporations. The company is based in Modi'in-Maccabim-Re'ut, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Modi'in-Maccabim-Re'ut"
    },
    "NXGN.TA": {
        "short_name": "NEXTGEN BIOMED LTD",
        "long_name": "Nextgen Biomed Ltd",
        "summary": "Nextgen Biomed Ltd does not have significant operations. The company was formerly known as Sela Group.Com Ltd. and changed its name to Nextgen Biomed Ltd in February 2010. Nextgen Biomed Ltd was incorporated in 1990 and is based in Tel Aviv, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Tel Aviv"
    },
    "NXTG.TA": {
        "short_name": "NEXTAGE THERAPEUTI",
        "long_name": "Nextage Therapeutics Ltd",
        "summary": "Nextage Therapeutics Ltd develops and commercializes in-vitro cancer diagnostic products and solutions worldwide. It offers CellDetect, a diagnostic platform for early cancer detection, including bladder cancer, cervical cancer, and prostate cancer. The company also provides BRONJ Test, a test for bisphosphonate-related osteonecrosis of the jaw. In addition, it offers gene expression, and biomarker and histochemical assays for early cancer detection and personalized medicine. Further, the company provides diagnostic solutions for multiple cancer diagnostic applications. The company was formerly known as Micromedic Technologies Ltd and changed its name to Nextage Therapeutics Ltd in August 2020. Nextage Therapeutics Ltd is based in Tel Aviv, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Tel Aviv"
    },
    "OWCP": {
        "short_name": "OWC PHARMACEUTICAL RESEARCH COR",
        "long_name": "OWC Pharmaceutical Research Corp.",
        "summary": "OWC Pharmaceutical Research Corp., through its subsidiary, One World Cannabis Ltd., engages in the research and development of cannabis-based medical products. It develops cannabis-based medical products for the treatment of various conditions, including multiple myeloma, psoriasis, post-traumatic stress disorder, chronic pain, and fibromyalgia. The company is also involved in developing cannabis soluble tablet delivery system. In addition, it provides consulting services to companies and governmental agencies related to international medical cannabis protocols and regulations. The company was formerly known as Dynamic Applications Corp. and changed its name to OWC Pharmaceutical Research Corp. in December 2014. OWC Pharmaceutical Research Corp. was founded in 2008 and is based in Ramat Gan, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Ramat Gan"
    },
    "PBDA.F": {
        "short_name": "PROTALIX BIOTHERAP.DL-,01",
        "long_name": "Protalix BioTherapeutics, Inc.",
        "summary": "Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; OPRX-106, an orally-delivered protein product candidate for the treatment of inflammatory bowel disease, as well as completed Phase IIa clinical trial for ulcerative colitis patients; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout. The company has agreements and partnerships with Pfizer; Funda\u00c3\u00a7\u00c3\u00a3o Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Israel",
        "city": "Karmiel"
    },
    "PHGE": {
        "short_name": "BiomX Inc.",
        "long_name": "BiomX Inc.",
        "summary": "BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "Israel",
        "city": "Ness Ziona"
    },
    "PHGE.TA": {
        "short_name": "BIOMX INC",
        "long_name": "BiomX Inc.",
        "summary": "BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Ness Ziona"
    },
    "PJT.F": {
        "short_name": "PLURISTEM THERAPEUTICS",
        "long_name": "Pluristem Therapeutics Inc.",
        "summary": "Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermittent claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant's patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Israel",
        "city": "Haifa"
    },
    "PLNT.TA": {
        "short_name": "PLANTARC BIO LTD",
        "long_name": "PlantArc Bio Ltd.",
        "summary": "PlantArcBio Ltd. operates as a biotechnology company for the enhancement of crop productivity and performance for food security. The company has developed a Direct In Plant gene discovery platform. It focuses on yield and abiotic stresses, insect resistance, herbicide tolerance, and disease control market segments. The company was founded in 2014 and is based in Giv'at Hen, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Giv\u00e2\u0080\u0099at Hen"
    },
    "PLX": {
        "short_name": "Protalix BioTherapeutics, Inc. ",
        "long_name": "Protalix BioTherapeutics, Inc.",
        "summary": "Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; OPRX-106, an orally-delivered protein product candidate for the treatment of inflammatory bowel disease, as well as completed Phase IIa clinical trial for ulcerative colitis patients; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout. The company has agreements and partnerships with Pfizer; Funda\u00c3\u00a7\u00c3\u00a3o Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "Israel",
        "city": "Karmiel"
    },
    "PLX.TA": {
        "short_name": "PROTALIX BIOTHERAP",
        "long_name": "Protalix BioTherapeutics, Inc.",
        "summary": "Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; OPRX-106, an orally-delivered protein product candidate for the treatment of inflammatory bowel disease, as well as completed Phase IIa clinical trial for ulcerative colitis patients; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout. The company has agreements and partnerships with Pfizer; Funda\u00c3\u00a7\u00c3\u00a3o Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Karmiel"
    },
    "PNAX.TA": {
        "short_name": "PANAXIA LABS ISRAE",
        "long_name": "Panaxia Labs Israel Ltd",
        "summary": "Panaxia Pharmaceutical Industries Ltd provides pharmaceutical solutions for patients and physicians. The company offers pharma-grade smokeless cannabis products, such as oral and sublingual tablets, medical oils, concentrations, pastilles, suppositories, topical creams, pain relief creams, and pain relief patches. Panaxia Pharmaceutical Industries Ltd has strategic partnerships with Ultra Health, Salus Biopharma, MPX Bioceutical Corporation, Rafa, Pharmocann, Seach Medical Cannabis Group, TevaAdir, Better, and Cann10. The company was incorporated in 2016 and is based in Lod, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Lod"
    },
    "PPBT": {
        "short_name": "Purple Biotech Ltd.",
        "long_name": "Purple Biotech Ltd.",
        "summary": "Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "Israel",
        "city": "Tel Aviv"
    },
    "PPBT.TA": {
        "short_name": "PURPLE BIOTECH",
        "long_name": "Purple Biotech Ltd.",
        "summary": "Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Tel Aviv"
    },
    "PRFX": {
        "short_name": "PainReform Ltd.",
        "long_name": "PainReform Ltd.",
        "summary": "PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of products for the treatment of pain in Israel. It develops PRF-110, a product based on local anesthetic ropivacaine, which completed Phase II clinical study in hernia repair. The company was founded in 2007 and is headquartered in Herzeliya, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Herzliya"
    },
    "PSTI": {
        "short_name": "Pluristem Therapeutics, Inc.",
        "long_name": "Pluristem Therapeutics Inc.",
        "summary": "Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermittent claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant's patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Haifa"
    },
    "PSTI.TA": {
        "short_name": "PLURISTEM THERAPEU",
        "long_name": "Pluristem Therapeutics Inc.",
        "summary": "Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermittent claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant's patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Haifa"
    },
    "PYPD": {
        "short_name": "PolyPid Ltd.",
        "long_name": "PolyPid Ltd.",
        "summary": "PolyPid Ltd. develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix platform. Its products include D-PLEX, an antibiotic drug reservoir that is implanted during surgery to prevent and treat surgical site infections; D-PLEX100 for the prevention of post-abdominal surgery incisional infection; BONYPID-1000, an antibiotic eluting \u00c3\u009f tri-calcium phosphate granule for bone related infections applications; and BONYPID\u00c2\u0096500, an antibiotic eluting bone graft substitute that fills and reconstructs periodontal and oral/maxillofacial defects, while protecting from infections. PolyPid Ltd. was founded in 2008 and is headquartered in Petach Tikva, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Israel",
        "city": "Petah Tikva"
    },
    "RDHL": {
        "short_name": "Redhill Biopharma Ltd.",
        "long_name": "RedHill Biopharma Ltd.",
        "summary": "RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, with a planned Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), a SK2 selective inhibitor targeting various indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and in Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, a Phase 2-stage serine protease inhibitor for cancer and inflammatory gastrointestinal diseases, and is also being evaluated for COVID-19; and RHB-106, an encapsulated bowel preparation. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Tel Aviv"
    },
    "REKA.TA": {
        "short_name": "REKAH PHARMA IND",
        "long_name": "Rekah Pharmaceutical Industry Ltd.",
        "summary": "Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company offers steroid tablets; antibiotics, including penicillin and cephalosporin; drops and ointments to treat allergies, infections, and dryness of the eyes; dermatological preparations; baby products; and vitamins and nutritional supplements. Its portfolio of products comprise approximately 280 drugs used in various medical fields. The company was founded in 1941 and is based in Holon, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Holon"
    },
    "ROSGQ": {
        "short_name": "ROSETTA GENOMICS LTD",
        "long_name": "Rosetta Genomics Ltd.",
        "summary": "Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer. In addition, the company offers ALK/ROS1 that are FISH-based predictive tests indicated for patients who are diagnosed with late stage lung cancer; and PCR gene mutation analysis for bladder, lung, colon, and melanoma patients. The company provides its diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists, and other specialists to facilitate them in serving their patients. It has a license agreement with Max Planck Innovation GmbH for the rights to its proprietary microRNAs for diagnostics and research purposes. The company also has a collaboration agreement with Meir Medical Center to develop a microRNA classifier relating to patients with non-small cell lung cancer considered for treatment with immuno oncology drugs. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Rehovot"
    },
    "RWLK": {
        "short_name": "ReWalk Robotics Ltd.",
        "long_name": "ReWalk Robotics Ltd.",
        "summary": "ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions. It offers ReWalk Personal for everyday use to paraplegic individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy used in hospitals and rehabilitation centers in the United States and Europe. The company is also developing ReWalk Restore, a soft suit exoskeleton for rehabilitation of individuals suffering from a stroke. It markets and sells its products directly to third party payers, institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was founded in 2001 and is headquartered in Yokneam Ilit, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Yokneam Illit"
    },
    "SHLTN.SW": {
        "short_name": "SHL TELEMEDICINE N",
        "long_name": "SHL Telemedicine Ltd.",
        "summary": "SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. The company offers smartheart, a personal mobile 12-lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; Cardio'B, a portable device to transmit a 12-lead ECG; and Cardio Beeper 12/12, a hand-held ECG transmitter device for personal use that transmits a full ECG reading to the monitoring center. It also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices; TeleWeight, a trans-telephonic weight monitoring device for personal use; TelePress, a remote blood pressure monitoring device for personal use; TeleBreather, a remote electronic handheld device to test the working of lungs; and TelePulse Oximeter, an electronic handheld diagnostic device to measure the saturation level of oxygen in blood, as well as pulse rate. The company offers its telemedicine services and devices to subscribers using telephonic and internet communication technology. It serves patients, health insurance companies, hospitals, clinics, physicians, and other health care providers. SHL Telemedicine Ltd. has a collaboration with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG. The company also has an agreement with the Hebrew University of Jerusalem to develop an artificial intelligence tool for predicting future life-threatening cardiac events based on 12 Lead ECG monitoring. SHL Telemedicine Ltd. was founded in 1987 and is headquartered in Tel Aviv, Israel.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "Israel",
        "city": "Tel Aviv"
    },
    "SLGL": {
        "short_name": "Sol-Gel Technologies Ltd.",
        "long_name": "Sol-Gel Technologies Ltd.",
        "summary": "Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, which has completed Phase II clinical trials for the treatment of acne vulgaris; Epsolay that has completed Phase II clinical trials for the treatment of papulopustular rosacea; SGT-210, a epidermal growth factor receptor inhibitor, which is in development for the treatment of palmoplantar keratoderma and non-melanoma skin cancer; and tapinarof and roflumilast to treat psoriasis and other dermatological indications. It is also involved in the development of generic topical dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo; and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Ness Ziona"
    },
    "SLGN.TA": {
        "short_name": "SOLEGREEN LTD",
        "long_name": "Solegreen Ltd",
        "summary": "Solegreen Ltd engages in the renewable energy business in Israel. It operates and maintains solar energy facilities. The company was formerly known as Procognia (Israel) Ltd. and changed its name to Solegreen Ltd in January 2015. Solegreen Ltd was founded in 2000 and is based in Herzliya, Israel. As per the transaction announced on September 3, 2018, Solegreen Ltd operates as a subsidiary of Lahav Green Mountains Ltd.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Tel Aviv"
    },
    "SZO.F": {
        "short_name": "SHL TELEMEDICINE  IS-,01",
        "long_name": "SHL Telemedicine Ltd.",
        "summary": "SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. The company offers smartheart, a personal mobile 12-lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; Cardio'B, a portable device to transmit a 12-lead ECG; and Cardio Beeper 12/12, a hand-held ECG transmitter device for personal use that transmits a full ECG reading to the monitoring center. It also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices; TeleWeight, a trans-telephonic weight monitoring device for personal use; TelePress, a remote blood pressure monitoring device for personal use; TeleBreather, a remote electronic handheld device to test the working of lungs; and TelePulse Oximeter, an electronic handheld diagnostic device to measure the saturation level of oxygen in blood, as well as pulse rate. The company offers its telemedicine services and devices to subscribers using telephonic and internet communication technology. It serves patients, health insurance companies, hospitals, clinics, physicians, and other health care providers. SHL Telemedicine Ltd. has a collaboration with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG. The company also has an agreement with the Hebrew University of Jerusalem to develop an artificial intelligence tool for predicting future life-threatening cardiac events based on 12 Lead ECG monitoring. SHL Telemedicine Ltd. was founded in 1987 and is headquartered in Tel Aviv, Israel.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Israel",
        "city": "Tel Aviv"
    },
    "TAL.F": {
        "short_name": "TARO PHAR.INDS. IS 0,0001",
        "long_name": "Taro Pharmaceutical Industries Ltd.",
        "summary": "Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprises allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Israel",
        "city": "Haifa"
    },
    "TARO": {
        "short_name": "Taro Pharmaceutical Industries ",
        "long_name": "Taro Pharmaceutical Industries Ltd.",
        "summary": "Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprises allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "Israel",
        "city": "Haifa"
    },
    "TEV.F": {
        "short_name": "TEVA PHARMACEUT. SP.ADR",
        "long_name": "Teva Pharmaceutical Industries Limited",
        "summary": "Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, the company provides specialty medicines for use in central nervous system and respiratory indications. Further, its products in the central nervous system and pain area comprise Copaxone for the treatment of relapsing forms of MS; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. Additionally, the company's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair/Cinqaero, and AirDuo RespiClick/ArmonAir RespiClick/AirDuo Digihaler for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. It has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Israel",
        "city": "Petah Tikva"
    },
    "TEVA": {
        "short_name": "Teva Pharmaceutical Industries ",
        "long_name": "Teva Pharmaceutical Industries Limited",
        "summary": "Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, the company provides specialty medicines for use in central nervous system and respiratory indications. Further, its products in the central nervous system and pain area comprise Copaxone for the treatment of relapsing forms of MS; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. Additionally, the company's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair/Cinqaero, and AirDuo RespiClick/ArmonAir RespiClick/AirDuo Digihaler for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. It has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "Israel",
        "city": "Petah Tikva"
    },
    "TEVA.TA": {
        "short_name": "TEVA PHARMA IND",
        "long_name": "Teva Pharmaceutical Industries Limited",
        "summary": "Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, the company provides specialty medicines for use in central nervous system and respiratory indications. Further, its products in the central nervous system and pain area comprise Copaxone for the treatment of relapsing forms of MS; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. Additionally, the company's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair/Cinqaero, and AirDuo RespiClick/ArmonAir RespiClick/AirDuo Digihaler for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. It has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Petah Tikva"
    },
    "TEVA.VI": {
        "short_name": "TEVA PHARMACEUTICAL ADR",
        "long_name": "Teva Pharmaceutical Industries Limited",
        "summary": "Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, the company provides specialty medicines for use in central nervous system and respiratory indications. Further, its products in the central nervous system and pain area comprise Copaxone for the treatment of relapsing forms of MS; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. Additionally, the company's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair/Cinqaero, and AirDuo RespiClick/ArmonAir RespiClick/AirDuo Digihaler for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. It has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Israel",
        "city": "Petah Tikva"
    },
    "TEVAN.MX": {
        "short_name": "TEVA PHARMACEUTICAL INDUSTRIES",
        "long_name": "Teva Pharmaceutical Industries Limited",
        "summary": "Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, the company provides specialty medicines for use in central nervous system and respiratory indications. Further, its products in the central nervous system and pain area comprise Copaxone for the treatment of relapsing forms of MS; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. Additionally, the company's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair/Cinqaero, and AirDuo RespiClick/ArmonAir RespiClick/AirDuo Digihaler for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. It has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Drugs - Generic",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "Israel",
        "city": "Petah Tikva"
    },
    "TEVJF": {
        "short_name": "TEVA PHARMACEUTICAL INDUSTRIES",
        "long_name": "Teva Pharmaceutical Industries Limited",
        "summary": "Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, the company provides specialty medicines for use in central nervous system and respiratory indications. Further, its products in the central nervous system and pain area comprise Copaxone for the treatment of relapsing forms of MS; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. Additionally, the company's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair/Cinqaero, and AirDuo RespiClick/ArmonAir RespiClick/AirDuo Digihaler for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. It has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Petah Tikva"
    },
    "TGTR.TA": {
        "short_name": "TOGETHER PHARMA",
        "long_name": "Together Pharma Ltd",
        "summary": "Together Pharma Ltd, through its subsidiary, Globus Pharma Ltd., engages in growing, producing, and distributing medical cannabis products in Israel. The company is headquartered in Ashkelon, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Ashkelon"
    },
    "TKUN.TA": {
        "short_name": "TIKUN OLAM - CANNB",
        "long_name": "Tikun Olam - Cannbit Pharmaceuticals Ltd",
        "summary": "A.L. Capital Holdings (2016) Ltd. does not have significant operations. The company was formerly known as Tamaris Holdings (1995) Ltd. and changed its name to A.L. Capital Holdings (2016) Ltd. in December 2015. The company was incorporated in 1995 and is based in Ramat Gan, Israel. A.L.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Ramat Gan"
    },
    "TOMDF": {
        "short_name": "TODOS MEDICAL LIMITED",
        "long_name": "Todos Medical Ltd.",
        "summary": "Todos Medical Ltd., a clinical-stage medical diagnostics company, develops and commercializes blood tests for the detection of immune-related diseases in Israel and internationally. The company develops Total Biochemical Infrared Analysis method, a proprietary method for screening of solid tumors using peripheral blood spectroscopy analysis; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis product includes TM-B1 and TM-B2 for breast cancer blood tests; and TM-C1 for testing of colorectal cancer. The company also imports and distributes personal protective equipment, test kits, and medical devices, such as ventilators. Todos Medical Ltd. has partnership with Moto-Para and Meridian HSN to provide a complete turnkey solution for on-site COVID testing. Todos Medical Ltd. was founded in 2010 and is headquartered in Rehovot, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Rehovot"
    },
    "TRPXY": {
        "short_name": "THERAPIX BIOSCIENCES LTD SPON A",
        "long_name": "SciSparc Ltd.",
        "summary": "Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110, which has completed Phase II a clinical trial for the treatment of Tourette syndrome and Obstructive Sleep Apnea; THX-160, which has completed two preliminary preclinical studies for the treatment of acute and chronic pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy. Therapix Biosciences Ltd. has a collaboration with The University of Calgary to evaluate the analgesic effect of Therapix's CB2R agonist proprietary drug candidate, THX-160. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Givatayim"
    },
    "VBLT": {
        "short_name": "Vascular Biogenics Ltd.",
        "long_name": "Vascular Biogenics Ltd.",
        "summary": "Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase 3 clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase 1/2 clinical trials for recurrent platinum-resistant ovarian cancer, as well as in Phase 2 clinical trials to treat GI tumors and has completed phase 2 clinical trial for the treatment of thyroid cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; and VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases. Further, the company is developing VB-201, a Lecinoxoid-based compound used to treat atherosclerosis that has completed phase II clinical, as well as in pre-clinical stage for the treatment of NASH and renal fibrosis. It is also developing VB-601 and 611 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi'in, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Israel",
        "city": "Hevel Modi'in"
    },
    "WIZP": {
        "short_name": "WIZE PHARMA INC",
        "long_name": "Wize Pharma, Inc.",
        "summary": "Wize Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the treatment of ophthalmic disorders. It has in-license rights to purchase, market, sell, and distribute LO2A for the treatment of dry eye syndrome (DES) and other ophthalmological illnesses, including Conjunctivochalasis and Sj\u00c3\u00b6gren's syndrome (Sj\u00c3\u00b6gren's) in the United States and other territories. The company is also conducting a Phase IV study for LO2A for DES in patients with Sj\u00c3\u00b6gren's. The company was formerly known as Star Night Technologies Ltd. and changed its name to Wize Pharma, Inc. in July 2015. Wize Pharma, Inc. was founded in 1982 and is headquartered in Hod Hasharon, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Hod HaSharon"
    },
    "XTLB": {
        "short_name": "XTL Biopharmaceuticals Ltd.",
        "long_name": "XTL Biopharmaceuticals Ltd.",
        "summary": "XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Ramat Gan, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Ramat Gan"
    },
    "YP2A.F": {
        "short_name": "BIOLIN.RX S.ADR 15 IL-,01",
        "long_name": "BioLineRx Ltd.",
        "summary": "BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech's TECENTRIQ (Atezolizumab) in Phase 1b/2 studies for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Modi'in, Israel.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Israel",
        "city": "Hevel Modi'in"
    }
}